Randomized Phase II Trial of Docetaxel plus Nivolumab or Docetaxel alone in patients with advanced non-squamous NSCLC and previous clinical benefit on treatment with single agent Nivolumab HCRN LUN15-233

G
Greg Durm, MD

Primary Investigator

Overview

The purpose of this study is to determine if using nivolumab and docetaxel together is better at controlling lung cancer than using docetaxel by itself.

Description

The purpose of this study is to determine if using nivolumab and docetaxel together is better at controlling lung cancer than using docetaxel by itself.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    lung cancer
  • Age: Between 18 Years - 100 Years
  • Gender: All

Inclusion Criteria
ECOG Performance Status of 0-2 within 30 days prior to registration
Histological or cytological confirmed non-squamous non-small cell lung cancer
Measurable disease
Must have has clinical benefit while on single agent nivolumab and now have disease progression
Most recent Nivolumab infusion must be completed within at least 6 weeks of randomization
Mandatory archival tumor tissue mus be identified prior to registration and obtained during the screening period
Mandatory biopsy after registration and prior to C1D1 treatment
Demonstrate adequate organ function
Exclusion Criteria
Prior treatment with Docetaxel
Previous autoimmune complication from Nivolumab requiring discontinuation of therapy or treatment with steroids
Previous discontinuation from Nivolumab due to an adverse event
Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L-2, anti-CD-137, or anti-CTLA-4 antibody
Any serious or uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy
Pregnant or breastfeeding
Known additional malignancy that is active and/or progressive requiring treatment; exceptions include basal cell or squamous cell skin cancer, in situ cervical or bladder cancer, or other cancer for which the subject has been disease-free for at least five years
Active central nervous system metastases
Active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required systemic corticosteroids/immunosuppressive medications EXCEPT for syndromes which would not be expected to recur in the absence of an external trigger
Test positive for hepatitis B surface antigen or hepatitis C ribonucleic acid
Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
History of allergy to study drug components


Additional Information:
Participants will not be paid for their participation.

Updated on 20 Nov 2022. Study ID: 1610963813 (LUN15-233)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center